Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • Over Rs 74 crore fine...

    Over Rs 74 crore fine on Himalaya, Intas Pharma, 2 Chemist Associations for anti-competitive trade practices

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2019-06-08T14:35:18+05:30  |  Updated On 16 Aug 2021 2:42 PM IST

    As per the CCI order, Himalaya Drug was fined Rs 18.59 crore while its three senior officials were fined a total of nearly Rs 4 lakh. Besides, Intas Pharmaceuticals was levied a penalty of Rs 55.59 crore and its four officials were fined Rs 11.78 lakh in total. Similarly, the chemist association was fined Rs 4.18 lakh and ICA Rs 39,812.


    New Delhi: The Competition Commission of India (CCI) has levied a total fine of over Rs 74 crore on pharma firms — Himalaya Drug Company and Intas Pharmaceuticals — along with its senior officials as well as two Madhya Pradesh-based drug groupings for indulging in anti-competitive trade practices. The two drug associations are Madhya Pradesh Chemists and Druggist Association (MPCDA) and Indore Chemists Association (ICA) as per an order by the CCI.


    The fair trade regulator held both the drug associations and pharma companies responsible for mandating the requirement of obtaining NOC (No Objection Certificate) prior to the appointment as stockists which resulted in limiting and controlling the supply of drugs and medicines in Madhya Pradesh.


    The act of entities contravened Section 3 of the Competition Act which pertains to the anti-competitive agreement, the regulator said in an order dated June 3.


    Regarding Himalaya Drug and Intas Pharmaceuticals, CCI noted that "despite advising the pharmaceutical companies not to facilitate such practices of the associations and directing the companies to bring to the notice of the Commission any kind of anti-competitive conduct being forced upon them by the trade association(s), the pharmaceutical companies have failed to demonstrate such ability."


    As per the CCI order, Himalaya Drug was fined Rs 18.59 crore while its three senior officials were fined a total of nearly Rs 4 lakh. Besides, Intas Pharmaceuticals was levied a penalty of Rs 55.59 crore and its four officials were fined Rs 11.78 lakh in total.


    Similarly, MPCDA was fined Rs 4.18 lakh and ICA Rs 39,812.


    In the matter of associations, the CCI said it has been proscribing anti-competitive practices of state and regional chemists and druggist associations in mandating NOC for the appointment of stockists.


    However, "despite various orders of the Commission passed in other matters and advisories issued by the Commission, the anti-competitive conduct on the part of the associations and their office bearers has been unrelenting," the regulator said while imposing fine on MPCDA and ICA.


    The ruling came on a complaint filed by Madhya Pradesh Chemists and Distributors Federation (MPCDF) which was aggrieved by the fact that one of its member, Pharma Agencies, despite having a valid license was denied the supply of products because of insistence on obtaining NOC from the two associations before being appointed stockist by pharmaceutical companies.


    MPCDF is affiliated to the All India Chemist and Distributors Federation which is a registered organisation of chemists and distributors in the state of Madhya Pradesh.



    Also Read: GSK, Pfizer gets CCI approval for consumer healthcare JV formation
    CCICCI imposes fineChemistchemist near meChemistsCompetition Commission of IndiaDruggistsHimalaya DrugICAIndore Chemists AssociationIntasIntas PharmaIntas Pharmaceuticalsll India Chemist and Distributors FederationMadhya PradeshMadhya Pradesh Chemists and Druggist AssociationMPCDAMPCDFno objection certificateNOCpharmapharma newspharma news india
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok